Table 1.
Study | Phase | Checkpoint inhibitor | Combination | Population | Number of patients | PD-L1 selection | ORR (RECIST 1.1) |
---|---|---|---|---|---|---|---|
KEYNOTE-01227 | 1b | Pembrolizumab | Nil |
TNBC ; pre-treated |
32 | PD-L1 positive (expression in stroma or ≥1% tumour cells) | 18.5% |
KEYNOTE-08629, 30 | 2 | Pembrolizumab | Nil |
TNBC ; Cohort A, pre-treated; Cohort B, first line |
Cohort A: 170 Cohort B: 52 |
Cohort A, unselected; Cohort B, PD-L1 positive (combined positive score ≥1%) |
Cohort A: 5% Cohort B: 23% |
Emens et al.31 | 1a | Atezolizumab | Nil |
TNBC ; majority pre-treated |
21 | PD-L1 positive (≥5% of infiltrating immune cells) | 24% |
Schmid et al.25 | 1a | Atezolizumab | Nil |
TNBC ; first line or pre-treated |
115 | Unselected | 10% |
Tolaney et al.32 | 1b/2 | Pembrolizumab | Eribulin |
TNBC ; first line or pre-treated |
39 | Unselected | 33.3% |
Adams et al.34 | 1b | Atezolizumab | Nab-paclitaxel |
TNBC ; first line or pre-treated |
32 | Unselected | 42% |
KEYNOTE-02836 | 1b | Pembrolizumab | Nil | ER+/HER2-; pre-treated | 25 | PD-L1 positive (expression in stroma or ≥1% tumour cells) | 12% |
JAVELIN39 | 1b | Avelumab | Nil |
Unselected ; pre-treated |
168 | Unselected | 5.4% |
Summary of recently presented studies of anti-PD1/PD-L1 therapy in metastatic breast cancer.
ORR objective response rate, TNBC triple-negative breast cancer